We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma-arisen at any extranodal site-received 90Y-ibritumomab tiuxetan at the activity of 0.4mCi/kg. Median age was 57years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3years, 12 of them after >5years. 90Y-ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients. © 2013 John Wiley & Sons, Ltd.

Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma

Paganelli, Giovanni
Penultimo
;
2014

Abstract

We evaluated clinical activity of 90Yttrium-ibritumomab (90Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma-arisen at any extranodal site-received 90Y-ibritumomab tiuxetan at the activity of 0.4mCi/kg. Median age was 57years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3years, 12 of them after >5years. 90Y-ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients. © 2013 John Wiley & Sons, Ltd.
Vanazzi, Anna; Grana, Chiara; Crosta, Cristiano; Pruneri, Giancarlo; Rizzo, Stefania; Radice, Davide; Pinto, Antonello; Calabrese, Liliana; Paganelli, Giovanni; Martinelli, Giovanni
File in questo prodotto:
File Dimensione Formato  
Vanazzi_et_al-2014-Hematological_Oncology.pdf

solo gestori archivio

Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 129.62 kB
Formato Adobe PDF
129.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2378230
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact